Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...
AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...
Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling ...
Companies that have grown profits and net profit margins over the past 12 months ...
Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends in the pharmaceutical sector.